Get a proposal

GLIOBLASTOMA · White paper

Glioblastoma Clinical Trials

Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.

Indication overview

About glioblastoma — and why its trials are hard

Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults, a WHO Grade IV astrocytic tumor with median survival typically 12 to 18 months and five-year survival under 10%. It is defined by marked intratumoral and intertumoral heterogeneity, microvascular proliferation, and pseudopalisading necrosis, with MGMT promoter methylation and IDH status as key prognostic/predictive markers. The therapeutic landscape is a graveyard of failures: standard of care still rests on maximal safe resection followed by radiotherapy plus temozolomide (the 2005 Stupp regimen, which added only about 2.5 months of median overall survival), with tumor-treating fields (Optune) extending survival in the EF-14 trial and bevacizumab approved for recurrence despite no overall-survival benefit. The blood-brain barrier, tumor heterogeneity, pseudoprogression, patient-selection bias, and underpowered designs drive frequent trial failure. Cilengitide (CENTRIC), rindopepimut (ACT IV), enzastaurin, veliparib, and cediranib all failed pivotal testing. Recent progress includes vorasidenib for IDH-mutant lower-grade glioma, though effective GBM-specific breakthroughs remain elusive.

Indication
Glioblastoma
ICD-10-CM
C71.9 — Malignant neoplasm of brain (glioblastoma)

Approved therapies & pivotal evidence

What's been approved — and by how much it moved the endpoint

Drug (brand)ApprovedSettingPivotal trialPrimary endpointMagnitude of benefit
Temozolomide (Temodar) 2005 (newly diagnosed GBM indication; initial approval 1999)Newly diagnosed GBM, concurrent with radiotherapy and as maintenance (Stupp regimen)EORTC-NCIC 26981/22981 (Stupp, NEJM 2005)Oral alkylator; median OS 14.6 vs 12.1 months (HR 0.63, P<0.0001), +~2.5 months; 2-year survival 26.5% vs 10.4%
Bevacizumab (Avastin) 2009Recurrent glioblastoma (accelerated approval)BRAIN (AVF3708g); confirmatory AVAglio / RTOG-0825Anti-VEGF antibody; objective response ~19.6-25.9%; improved PFS but no overall-survival benefit in AVAglio/RTOG-0825
Tumor-treating fields (Optune (NovoTTF-100A)) 2015 (newly diagnosed GBM; initial recurrent-GBM approval 2011)Newly diagnosed GBM with maintenance temozolomide; monotherapy for recurrenceEF-14 (newly diagnosed); EF-11 (recurrent)Alternating electric fields disrupt mitosis; EF-14 median OS 20.9 vs 16.0 months and PFS 6.7 vs 4.0 months with adequate compliance
Carmustine (BiCNU / Gliadel wafer) 1977 (BiCNU); 1996/2003 (Gliadel wafer)Combination chemotherapy; implantable wafer in resection cavity (Gliadel largely discontinued)Gliadel wafer pivotal trial (newly diagnosed malignant glioma)Alkylator cross-linking DNA; wafer median survival 13.9 vs 11.6 months, ~29% reduction in risk of death (P=0.03); Gliadel later discontinued
Lomustine (Gleostine) 1976Recurrent/second-line GBM, often in combination regimensApproved on historical clinical evidence; used as comparator in modern recurrent-GBM trialsOral nitrosourea alkylator; modest survival benefit in recurrence; delayed myelosuppression is dose-limiting
Vorasidenib (Voranigo) 2024Grade 2 IDH-mutant astrocytoma/oligodendroglioma after surgery (NOT approved for Grade IV GBM)INDIGO (NCT04164901)Brain-penetrant IDH1/2 inhibitor; significantly prolonged progression-free survival vs placebo; relevant to IDH-mutant glioma, not classic GBM

Where trials have failed

Drugs that missed their endpoint — and what contributed

The most instructive lessons in glioblastoma development come from programmes that failed the endpoint that mattered.

Drug / trialEndpoint outcomeWhat contributed
Cilengitide — CENTRIC (EORTC 26071-22072, Phase III)Did not improve overall survival when added to temozolomide/radiotherapy in MGMT-methylated newly diagnosed GBMIntegrin (alphavbeta3/alphavbeta5) inhibitor; no survival benefit; development for GBM discontinued
Rindopepimut — ACT IV (Phase III)Failed to improve overall survival in EGFRvIII-positive newly diagnosed GBM; discontinuedEGFRvIII peptide vaccine; antigen loss and tumor heterogeneity undermined single-target vaccination
Cediranib — REGAL and combination Phase II/III (recurrent GBM)Failed to significantly improve OS or PFSVEGFR inhibitor; anti-angiogenesis alone insufficient given redundant angiogenic pathways and pseudoresponse

Choosing the right endpoint

Primary endpoints that matter in glioblastoma trials

  • Overall survival (OS) — Gold-standard endpoint; confounded by tumor heterogeneity and post-progression salvage therapies; addressed with molecular stratification
  • Progression-free survival (PFS) — Time without progression; complicated by pseudoprogression after chemoradiation and imaging variability; RANO criteria standardize assessment
  • Objective response rate (ORR) — Imaging-based tumor reduction; responses often short-lived and irregular tumors are hard to measure; benefits from centralized review
  • Health-related quality of life — EORTC QLQ-C30 / FACT-Br; important given aggressive disease and treatment toxicity; subject to reporting bias
  • Biomarker-based endpoints — MGMT promoter methylation and IDH status predict alkylator response and prognosis; require validation and account for heterogeneity

How iNGENū runs glioblastoma trials

Physician-led design, built for FDA submission

Endpoint & biomarker strategy

Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.

FDA-ready data

Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.

Faster, lower-cost delivery

~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.

PDF
Navigating the Complexities of Glioblastoma Clinical Trials
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Download white paper

Frequently asked questions

Glioblastoma clinical trials — FAQs

What is the standard of care for newly diagnosed glioblastoma?
Maximal safe surgical resection followed by radiotherapy with concurrent and maintenance temozolomide, the 2005 Stupp regimen, which extended median survival from 12.1 to 14.6 months. Tumor-treating fields (Optune) added to maintenance temozolomide further improved median survival to about 20.9 months in the EF-14 trial. Prognosis nonetheless remains poor.
Why has glioblastoma drug development failed so often?
The blood-brain barrier limits drug delivery, tumors are profoundly heterogeneous and develop resistance, and pseudoprogression/pseudoresponse confound imaging endpoints. Trials are frequently underpowered and enroll favorable-prognosis patients. High-profile failures include cilengitide (CENTRIC), rindopepimut (ACT IV), enzastaurin, veliparib, and cediranib.
Does bevacizumab improve survival in glioblastoma?
No. Bevacizumab (Avastin) received accelerated approval in 2009 for recurrent GBM based on response rate, but the AVAglio and RTOG-0825 trials showed it improves progression-free survival without extending overall survival. It is used mainly to control symptoms and edema rather than to prolong life.

Ready to discuss your glioblastoma trial?

Talk to our physician-led team about an FDA-ready, cost-efficient trial design.

Request a proposal